Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer

@inproceedings{Park2015RoleOH,
  title={Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer},
  author={Yeon Hee Park and H Shin and Hae Hyun Jung and Yoon-La Choi and TaeJin Ahn and Kyunghee Park and Aeri Lee and In-Gu Do and Ji-Yeon Kim and Jin Seok Ahn and Woong-Yang Park and Young-Hyuck Im},
  booktitle={Oncotarget},
  year={2015}
}
In women with metastatic breast cancer (MBC), introduction of the anti-HER2 (human epidermal growth factor receptor-2) directed therapies including trastuzumab, pertuzumab, lapatinib, and/or trastuzumab-DM1 has markedly improved overall survival. However, not all cases of HER2-positive breast tumours derive similar benefit from HER2-directed therapy, and a significant number of patients experience disease progression because of primary or acquired resistance to anti-HER2-directed therapies. We… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
13 Citations
48 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Similar Papers

Loading similar papers…